Conv. Plasma
Nigella Sativa

All molnupiravir studies
Meta analysis
study COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Molnupiravir for Intra-Household Prevention of COVID-19: the MOVe-AHEAD Randomized, Placebo-Controlled Trial

Alpizar et al., Journal of Infection, doi:10.1016/j.jinf.2023.08.016, MOVe-AHEAD, NCT04939428
Sep 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
Symp. case, MITT 24% Improvement Relative Risk Molnupiravir  MOVe-AHEAD  Prophylaxis  DB RCT Is prophylaxis with molnupiravir beneficial for COVID-19? Double-blind RCT 1,527 patients in multiple countries Fewer symptomatic cases with molnupiravir (not stat. sig., p=0.057) Alpizar et al., J. Infection, September 2023 Favorsmolnupiravir Favorscontrol 0 0.5 1 1.5 2+
PEP RCT 1,527 patients showing lower COVID-19 cases with molnupiravir, without statistical significance.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer1-9. Multiple analyses have identified variants potentially created by molnupiravir10-13.
risk of symptomatic case, 24.2% lower, RR 0.76, p = 0.06, treatment 78 of 763 (10.2%), control 103 of 764 (13.5%), NNT 31, MITT.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alpizar et al., 8 Sep 2023, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 18 authors, trial NCT04939428 (history) (MOVe-AHEAD).
This PaperMolnupiravirAll
{ 'indexed': {'date-parts': [[2024, 4, 2]], 'date-time': '2024-04-02T10:54:22Z', 'timestamp': 1712055262731}, 'reference-count': 63, 'publisher': 'Elsevier BV', 'issue': '5', 'license': [ { 'start': { 'date-parts': [[2023, 11, 1]], 'date-time': '2023-11-01T00:00:00Z', 'timestamp': 1698796800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2023, 9, 18]], 'date-time': '2023-09-18T00:00:00Z', 'timestamp': 1694995200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': ''}], 'funder': [{'DOI': '10.13039/100009947', 'name': 'Merck Sharp and Dohme', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': [ '', '', '', '', '', '', '', ''], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 11]]}, 'DOI': '10.1016/j.jinf.2023.08.016', 'type': 'journal-article', 'created': {'date-parts': [[2023, 9, 9]], 'date-time': '2023-09-09T22:16:31Z', 'timestamp': 1694297791000}, 'page': '392-402', 'update-policy': '', 'source': 'Crossref', 'is-referenced-by-count': 2, 'title': 'Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, ' 'placebo-controlled trial', 'prefix': '10.1016', 'volume': '87', 'author': [ {'given': 'Sady A.', 'family': 'Alpizar', 'sequence': 'first', 'affiliation': []}, {'given': 'Jose', 'family': 'Accini', 'sequence': 'additional', 'affiliation': []}, {'given': 'Duane C.', 'family': 'Anderson', 'sequence': 'additional', 'affiliation': []}, {'given': 'Basem', 'family': 'Eysa', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': '', 'authenticated-orcid': False, 'given': 'Isaí', 'family': 'Medina-Piñón', 'sequence': 'additional', 'affiliation': []}, {'given': 'Norio', 'family': 'Ohmagari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mykola M.', 'family': 'Ostrovskyy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Angela', 'family': 'Aggrey-Amable', 'sequence': 'additional', 'affiliation': []}, {'given': 'Karen', 'family': 'Beck', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': '', 'authenticated-orcid': False, 'given': 'Dana', 'family': 'Byrne', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': '', 'authenticated-orcid': False, 'given': 'Staci', 'family': 'Grayson', 'sequence': 'additional', 'affiliation': []}, {'given': 'Peggy M.T.', 'family': 'Hwang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Julia D.', 'family': 'Lonchar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Julie', 'family': 'Strizki', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yayun', 'family': 'Xu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amanda', 'family': 'Paschke', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carisa S.', 'family': 'De Anda', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pamela S.', 'family': 'Sears', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.jinf.2023.08.016_bib1', 'unstructured': 'World Health Organization. WHO Coronavirus (COVID-19) Dashboard (Updated ' 'September 05, 2023). World Health Organization (WHO); 2023. Available ' 'at: [Accessed on September 12, 2023].'}, { 'key': '10.1016/j.jinf.2023.08.016_bib2', 'doi-asserted-by': 'crossref', 'first-page': '21', 'DOI': '10.1016/j.euroneuro.2021.10.004', 'article-title': 'Results of the COVID-19 mental health international for the general ' 'population (COMET-G) study', 'volume': '54', 'author': 'Fountoulakis', 'year': '2022', 'journal-title': 'Eur Neuropsychopharmacol'}, { 'issue': '16', 'key': '10.1016/j.jinf.2023.08.016_bib3', 'doi-asserted-by': 'crossref', 'first-page': '1604', 'DOI': '10.1001/jama.2022.18931', 'article-title': 'Estimated global proportions of individuals with persistent fatigue, ' 'cognitive, and respiratory symptom clusters following symptomatic ' 'COVID-19 in 2020 and 2021', 'volume': '328', 'author': 'Wulf Hanson', 'year': '2022', 'journal-title': 'JAMA'}, { 'issue': '10334', 'key': '10.1016/j.jinf.2023.08.016_bib4', 'doi-asserted-by': 'crossref', 'first-page': '1513', 'DOI': '10.1016/S0140-6736(21)02796-3', 'article-title': 'Estimating excess mortality due to the COVID-19 pandemic: a systematic ' 'analysis of COVID-19-related mortality, 2020-21', 'volume': '399', 'year': '2022', 'journal-title': 'Lancet'}, { 'issue': '10312', 'key': '10.1016/j.jinf.2023.08.016_bib5', 'doi-asserted-by': 'crossref', 'first-page': '1700', 'DOI': '10.1016/S0140-6736(21)02143-7', 'article-title': 'Global prevalence and burden of depressive and anxiety disorders in 204 ' 'countries and territories in 2020 due to the COVID-19 pandemic', 'volume': '398', 'year': '2021', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.jinf.2023.08.016_bib6', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fpubh.2023.1112383', 'article-title': 'Post-acute COVID-19 symptom risk in hospitalized and non-hospitalized ' 'COVID-19 survivors: A systematic review and meta-analysis', 'volume': '11', 'author': 'Yuan', 'year': '2023', 'journal-title': 'Front Public Health'}, { 'key': '10.1016/j.jinf.2023.08.016_bib7', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eclinm.2021.101019', 'article-title': 'Characterizing long COVID in an international cohort: 7 months of ' 'symptoms and their impact', 'volume': '38', 'author': 'Davis', 'year': '2021', 'journal-title': 'EClinicalMedicine'}, { 'issue': '8', 'key': '10.1016/j.jinf.2023.08.016_bib8', 'doi-asserted-by': 'crossref', 'first-page': '1126', 'DOI': '10.7326/M22-0729', 'article-title': 'Effect of molnupiravir on biomarkers, respiratory interventions, and ' 'medical services in COVID-19: A randomized, placebo-controlled trial', 'volume': '175', 'author': 'Johnson', 'year': '2022', 'journal-title': 'Ann Intern Med'}, { 'issue': '7', 'key': '10.1016/j.jinf.2023.08.016_bib9', 'doi-asserted-by': 'crossref', 'first-page': '699', 'DOI': '10.1007/s40273-022-01168-0', 'article-title': 'Cost-effectiveness analysis of molnupiravir versus best supportive care ' 'for the treatment of outpatient COVID-19 in adults in the US', 'volume': '40', 'author': 'Goswami', 'year': '2022', 'journal-title': 'Pharmacoeconomics'}, { 'key': '10.1016/j.jinf.2023.08.016_bib10', 'series-title': 'Emerging variants of SARS-CoV-2 and novel therapeutics against ' 'coronavirus (COVID-19)', 'author': 'Aleem', 'year': '2023'}, { 'key': '10.1016/j.jinf.2023.08.016_bib11', 'series-title': 'Features, evaluation, and treatment of coronavirus (COVID-19)', 'author': 'Cascella', 'year': '2022'}, { 'issue': '6', 'key': '10.1016/j.jinf.2023.08.016_bib12', 'first-page': '649', 'article-title': 'The challenge of asymptomatic carriers of COVID-19: a rapid review of ' 'literature', 'volume': '22', 'author': 'Albavera-Hernandez', 'year': '2023', 'journal-title': 'Rev Salud Publica'}, { 'key': '10.1016/j.jinf.2023.08.016_bib13', 'doi-asserted-by': 'crossref', 'first-page': '46', 'DOI': '10.1016/j.ijid.2023.03.025', 'article-title': 'Impact of public health and social measures on contact dynamics during ' 'a SARS-CoV-2 Omicron variant outbreak in Quanzhou, China, March to ' 'April 2022', 'volume': '131', 'author': 'Guo', 'year': '2023', 'journal-title': 'Int J Infect Dis'}, { 'key': '10.1016/j.jinf.2023.08.016_bib14', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1136/bmjpo-2022-001718', 'article-title': 'Systematic review of outbreaks of COVID-19 within households in the ' 'European region when the child is the index case', 'volume': '7', 'author': 'Vardavas', 'year': '2023', 'journal-title': 'BMJ Paediatr Open'}, { 'issue': '2', 'key': '10.1016/j.jinf.2023.08.016_bib15', 'article-title': 'Household transmission of SARS-CoV-2 during the Omicron wave in ' 'Shanghai, China: a case-ascertained study', 'volume': '17', 'author': 'Wei', 'year': '2023', 'journal-title': 'Influenza Other Respir Virus'}, { 'issue': '2', 'key': '10.1016/j.jinf.2023.08.016_bib16', 'doi-asserted-by': 'crossref', 'first-page': '178', 'DOI': '10.1016/j.cmi.2021.10.015', 'article-title': 'Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 ' '(SARS-CoV-2) from pre and asymptomatic infected individuals: a ' 'systematic review', 'volume': '28', 'author': 'Jefferson', 'year': '2022', 'journal-title': 'Clin Microbiol Infect'}, { 'issue': '6', 'key': '10.1016/j.jinf.2023.08.016_bib17', 'doi-asserted-by': 'crossref', 'first-page': '666', 'DOI': '10.1016/j.jinf.2022.10.027', 'article-title': 'Viral dynamics of the SARS-CoV-2 Omicron variant among household ' 'contacts with 2 or 3 COVID-19 vaccine doses', 'volume': '85', 'author': 'Kandel', 'year': '2022', 'journal-title': 'J Infect'}, { 'issue': '5', 'key': '10.1016/j.jinf.2023.08.016_bib18', 'doi-asserted-by': 'crossref', 'first-page': '803', 'DOI': '10.1111/irv.13002', 'article-title': 'Transmission of SARS-CoV-2 in standardised first few X cases and ' 'household transmission investigations: a systematic review and ' 'meta-analysis', 'volume': '16', 'author': 'Lewis', 'year': '2022', 'journal-title': 'Influenza Other Respir Virus'}, { 'issue': '12', 'key': '10.1016/j.jinf.2023.08.016_bib19', 'doi-asserted-by': 'crossref', 'first-page': '2126', 'DOI': '10.1093/cid/ciad074', 'article-title': 'Infection-induced immunity is associated with protection against ' 'SARS-CoV-2 infection and decreased infectivity', 'volume': '76', 'author': 'Frutos', 'year': '2023', 'journal-title': 'Clin Infect Dis'}, { 'issue': '1', 'key': '10.1016/j.jinf.2023.08.016_bib20', 'doi-asserted-by': 'crossref', 'first-page': 'ofac676', 'DOI': '10.1093/ofid/ofac676', 'article-title': 'Association between population-level factors and household secondary ' 'attack rate of SARS-CoV-2: a systematic review and meta-analysis', 'volume': '10', 'author': 'Wang', 'year': '2023', 'journal-title': 'Open Forum Infect Dis'}, { 'issue': '1', 'key': '10.1016/j.jinf.2023.08.016_bib21', 'doi-asserted-by': 'crossref', 'first-page': '3801', 'DOI': '10.1038/s41467-022-31441-x', 'article-title': 'Revisiting COVID-19 vaccine hesitancy around the world using data from ' '23 countries in 2021', 'volume': '13', 'author': 'Lazarus', 'year': '2022', 'journal-title': 'Nat Commun'}, { 'issue': '10278', 'key': '10.1016/j.jinf.2023.08.016_bib22', 'doi-asserted-by': 'crossref', 'first-page': '1023', 'DOI': '10.1016/S0140-6736(21)00306-8', 'article-title': 'Challenges in ensuring global access to COVID-19 vaccines: production, ' 'affordability, allocation, and deployment', 'volume': '397', 'author': 'Wouters', 'year': '2021', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.jinf.2023.08.016_bib23', 'doi-asserted-by': 'crossref', 'first-page': '1078009', 'DOI': '10.3389/fpubh.2023.1078009', 'article-title': 'COVID-19 vaccine hesitancy among parents in Low- and Middle-Income ' 'Countries: a meta-analysis', 'volume': '11', 'author': 'Abu El Kheir-Mataria', 'year': '2023', 'journal-title': 'Front Public Health'}, { 'issue': '10328', 'key': '10.1016/j.jinf.2023.08.016_bib24', 'doi-asserted-by': 'crossref', 'first-page': '924', 'DOI': '10.1016/S0140-6736(22)00152-0', 'article-title': 'Duration of effectiveness of vaccines against SARS-CoV-2 infection and ' 'COVID-19 disease: results of a systematic review and meta-regression', 'volume': '399', 'author': 'Feikin', 'year': '2022', 'journal-title': 'Lancet'}, { 'issue': '4', 'key': '10.1016/j.jinf.2023.08.016_bib25', 'doi-asserted-by': 'crossref', 'first-page': '642', 'DOI': '10.1016/j.ajpath.2022.01.007', 'article-title': 'Signals of significantly increased vaccine breakthrough, decreased ' 'hospitalization rates, and less severe disease in patients with ' 'coronavirus disease 2019 caused by the Omicron variant of Severe Acute ' 'Respiratory Syndrome Coronavirus 2 in Houston, Texas', 'volume': '192', 'author': 'Christensen', 'year': '2022', 'journal-title': 'Am J Pathol'}, { 'issue': '9', 'key': '10.1016/j.jinf.2023.08.016_bib26', 'doi-asserted-by': 'crossref', 'first-page': '4234', 'DOI': '10.1002/jmv.27871', 'article-title': 'Clinical manifestations of COVID-19 breakthrough infections: a ' 'systematic review and meta-analysis', 'volume': '94', 'author': 'Lee', 'year': '2022', 'journal-title': 'J Med Virol'}, { 'key': '10.1016/j.jinf.2023.08.016_bib27', 'doi-asserted-by': 'crossref', 'DOI': '10.1017/S0950268823000249', 'article-title': 'Characteristics of patients with SARS-COV-2 PCR re-positivity after ' 'recovering from COVID-19', 'volume': '151', 'author': 'Hu', 'year': '2023', 'journal-title': 'Epidemiol Infect'}, { 'key': '10.1016/j.jinf.2023.08.016_bib28', 'doi-asserted-by': 'crossref', 'first-page': '4', 'DOI': '10.3390/ijerph20043335', 'article-title': 'Severity and outcomes of SARS-CoV-2 reinfection compared with primary ' 'infection: A systematic review and meta-analysis', 'volume': '20', 'author': 'Deng', 'year': '2023', 'journal-title': 'Int J Environ Res Public Health'}, { 'issue': '2', 'key': '10.1016/j.jinf.2023.08.016_bib29', 'doi-asserted-by': 'crossref', 'first-page': '367', 'DOI': '10.1007/s40121-022-00753-2', 'article-title': 'Durability of vaccine-induced and natural immunity against COVID-19: a ' 'narrative review', 'volume': '12', 'author': 'Pooley', 'year': '2023', 'journal-title': 'Infect Dis Ther'}, { 'issue': '3', 'key': '10.1016/j.jinf.2023.08.016_bib30', 'doi-asserted-by': 'crossref', 'first-page': '440', 'DOI': '10.1086/381128', 'article-title': 'Management of influenza in households: a prospective, randomized ' 'comparison of oseltamivir treatment with or without postexposure ' 'prophylaxis', 'volume': '189', 'author': 'Hayden', 'year': '2004', 'journal-title': 'J Infect Dis'}, { 'issue': '4', 'key': '10.1016/j.jinf.2023.08.016_bib31', 'doi-asserted-by': 'crossref', 'first-page': '309', 'DOI': '10.1056/NEJMoa1915341', 'article-title': 'Baloxavir marboxil for prophylaxis against influenza in household ' 'contacts', 'volume': '383', 'author': 'Ikematsu', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'issue': '3', 'key': '10.1016/j.jinf.2023.08.016_bib32', 'first-page': '362', 'article-title': 'Pre-exposure prophylaxis for viral infections other than HIV', 'volume': '30', 'author': 'Soriano', 'year': '2022', 'journal-title': 'Infez Med'}, { 'key': '10.1016/j.jinf.2023.08.016_bib33', 'unstructured': 'United States Food and Drug Administration. FDA authorizes bamlanivimab ' 'and etesevimab monoclonal antibody therapy for post-exposure prophylaxis ' '(prevention) for COVID-19. U.S. Food & Drug Administration (FDA); 2021 ' '(updated September 16, 2021). Available at: ' ' ' '[Accessed on: September 13, 2023].'}, { 'issue': '13', 'key': '10.1016/j.jinf.2023.08.016_bib34', 'doi-asserted-by': 'crossref', 'first-page': '1184', 'DOI': '10.1056/NEJMoa2109682', 'article-title': 'Subcutaneous REGEN-COV antibody combination to prevent Covid-19', 'volume': '385', 'author': "O'Brien", 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.jinf.2023.08.016_bib35', 'unstructured': 'National Institues of Health. Coronavirus Disease 2019 (COVID-19) ' 'treatment guidelines (Updated August 22, 2023). National Institues of ' 'Health (NIH); 2023. Available at ' ' [Accessed on: September ' '13, 2023].'}, { 'issue': '5', 'key': '10.1016/j.jinf.2023.08.016_bib36', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/AAC.02428-20', 'article-title': 'Human safety, tolerability, and pharmacokinetics of molnupiravir, a ' 'novel broad-spectrum oral antiviral agent with activity against ' 'SARS-CoV-2', 'volume': '65', 'author': 'Painter', 'year': '2021', 'journal-title': 'Antimicrob Agents Chemother'}, { 'issue': '541', 'key': '10.1016/j.jinf.2023.08.016_bib37', 'doi-asserted-by': 'crossref', 'DOI': '10.1126/scitranslmed.abb5883', 'article-title': 'An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in ' 'human airway epithelial cell cultures and multiple coronaviruses in ' 'mice', 'volume': '12', 'author': 'Sheahan', 'year': '2020', 'journal-title': 'Sci Transl Med'}, { 'key': '10.1016/j.jinf.2023.08.016_bib38', 'doi-asserted-by': 'crossref', 'first-page': '451', 'DOI': '10.1038/s41586-021-03312-w', 'article-title': 'SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801', 'volume': '591', 'author': 'Wahl', 'year': '2021', 'journal-title': 'Nature'}, { 'issue': '8', 'key': '10.1016/j.jinf.2023.08.016_bib39', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/AAC.00766-18', 'article-title': 'Orally efficacious broad-spectrum ribonucleoside analog inhibitor of ' 'influenza and respiratory syncytial viruses', 'volume': '62', 'author': 'Yoon', 'year': '2018', 'journal-title': 'Antimicrob Agents Chemother'}, { 'issue': '6', 'key': '10.1016/j.jinf.2023.08.016_bib40', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients', 'volume': '386', 'author': 'Jayk Bernal', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.jinf.2023.08.016_bib41', 'doi-asserted-by': 'crossref', 'first-page': '13', 'DOI': '10.1172/jci.insight.160108', 'article-title': 'Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the ' 'hamster model', 'volume': '7', 'author': 'Rosenke', 'year': '2022', 'journal-title': 'JCI Insight'}, { 'issue': '5', 'key': '10.1016/j.jinf.2023.08.016_bib42', 'doi-asserted-by': 'crossref', 'first-page': '749', 'DOI': '10.1093/infdis/jiab361', 'article-title': 'Molnupiravir inhibits the replication of the emerging SARS-CoV-2 ' 'variants of concern (VoCs) in a hamster infection model', 'volume': '224', 'author': 'Abdelnabi', 'year': '2021', 'journal-title': 'J Infect Dis'}, { 'issue': '1', 'key': '10.1016/j.jinf.2023.08.016_bib43', 'doi-asserted-by': 'crossref', 'first-page': '4416', 'DOI': '10.1038/s41467-022-32045-1', 'article-title': 'SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in ' 'severe COVID-19 dwarf hamster model', 'volume': '13', 'author': 'Lieber', 'year': '2022', 'journal-title': 'Nat Commun'}, { 'issue': '10', 'key': '10.1016/j.jinf.2023.08.016_bib44', 'doi-asserted-by': 'crossref', 'first-page': '995', 'DOI': '10.1056/NEJMc2119407', 'article-title': 'Efficacy of antibodies and antiviral drugs against Covid-19 Omicron ' 'variant', 'volume': '386', 'author': 'Takashita', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'issue': '24', 'key': '10.1016/j.jinf.2023.08.016_bib45', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/JVI.01348-19', 'article-title': 'Small-molecule antiviral beta-d-N (4)-hydroxycytidine inhibits a ' 'proofreading-intact coronavirus with a high genetic barrier to ' 'resistance', 'volume': '93', 'author': 'Agostini', 'year': '2019', 'journal-title': 'J Virol'}, { 'issue': '3', 'key': '10.1016/j.jinf.2023.08.016_bib46', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/JVI.01965-17', 'article-title': 'β-d-N4-hydroxycytidine is a potent anti-alphavirus compound that ' 'induces a high level of mutations in the viral genome', 'volume': '92', 'author': 'Urakova', 'year': '2018', 'journal-title': 'J Virol'}, { 'issue': '10373', 'key': '10.1016/j.jinf.2023.08.016_bib47', 'doi-asserted-by': 'crossref', 'first-page': '281', 'DOI': '10.1016/S0140-6736(22)02597-1', 'article-title': 'Molnupiravir plus usual care versus usual care alone as early treatment ' 'for adults with COVID-19 at increased risk of adverse outcomes ' '(PANORAMIC): an open-label, platform-adaptive randomised controlled ' 'trial', 'volume': '401', 'author': 'Butler', 'year': '2023', 'journal-title': 'Lancet'}, { 'issue': '4', 'key': '10.1016/j.jinf.2023.08.016_bib48', 'doi-asserted-by': 'crossref', 'first-page': '352', 'DOI': '10.1016/j.jinf.2023.02.012', 'article-title': 'Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and ' 'sotrovimab on preventing hospital admission among higher-risk patients ' 'with COVID-19 in Wales: A retrospective cohort study', 'volume': '86', 'author': 'Evans', 'year': '2023', 'journal-title': 'J Infect'}, { 'issue': '6', 'key': '10.1016/j.jinf.2023.08.016_bib49', 'doi-asserted-by': 'crossref', 'first-page': '3114', 'DOI': '10.1038/s41596-021-00536-y', 'article-title': 'Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque ' 'reduction neutralization, microneutralization and pseudotyped virus ' 'neutralization assays', 'volume': '16', 'author': 'Bewley', 'year': '2021', 'journal-title': 'Nat Protoc'}, { 'issue': '526', 'key': '10.1016/j.jinf.2023.08.016_bib50', 'doi-asserted-by': 'crossref', 'first-page': '793', 'DOI': '10.1259/0007-1285-44-526-793', 'article-title': 'Repeated assessment of results in clinical trials of cancer treatment', 'volume': '44', 'author': 'Haybittle', 'year': '1971', 'journal-title': 'Br J Radio'}, { 'issue': '6', 'key': '10.1016/j.jinf.2023.08.016_bib51', 'doi-asserted-by': 'crossref', 'first-page': '585', 'DOI': '10.1038/bjc.1976.220', 'article-title': 'Design and analysis of randomized clinical trials requiring prolonged ' 'observation of each patient. I. Introduction and design', 'volume': '34', 'author': 'Peto', 'year': '1976', 'journal-title': 'Br J Cancer'}, { 'issue': 'Suppl.2', 'key': '10.1016/j.jinf.2023.08.016_bib52', 'doi-asserted-by': 'crossref', 'first-page': 'S138', 'DOI': '10.1093/cid/ciaa1558', 'article-title': 'The household secondary attack rate of Severe Acute Respiratory ' 'Syndrome Coronavirus 2 (SARS-CoV-2): a rapid review', 'volume': '73', 'author': 'Fung', 'year': '2021', 'journal-title': 'Clin Infect Dis'}, { 'issue': '10', 'key': '10.1016/j.jinf.2023.08.016_bib53', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0240205', 'article-title': 'What do we know about SARS-CoV-2 transmission? A systematic review and ' 'meta-analysis of the secondary attack rate and associated risk factors', 'volume': '15', 'author': 'Koh', 'year': '2020', 'journal-title': 'PLoS One'}, { 'issue': '12', 'key': '10.1016/j.jinf.2023.08.016_bib54', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2020.31756', 'article-title': 'Household transmission of SARS-CoV-2: a systematic review and ' 'meta-analysis', 'volume': '3', 'author': 'Madewell', 'year': '2020', 'journal-title': 'JAMA Netw Open'}, { 'issue': '11', 'key': '10.1016/j.jinf.2023.08.016_bib55', 'doi-asserted-by': 'crossref', 'first-page': '879', 'DOI': '10.7326/M20-2671', 'article-title': 'Contact settings and risk for transmission in 3410 close contacts of ' 'patients With COVID-19 in Guangzhou, China: a Prospective Cohort Study', 'volume': '173', 'author': 'Luo', 'year': '2020', 'journal-title': 'Ann Intern Med'}, { 'issue': '6', 'key': '10.1016/j.jinf.2023.08.016_bib56', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/mbio.02916-22', 'article-title': 'Why molnupiravir fails in hospitalized patients', 'volume': '13', 'author': 'Brown', 'year': '2022', 'journal-title': 'mBio'}, { 'issue': '2', 'key': '10.1016/j.jinf.2023.08.016_bib57', 'doi-asserted-by': 'crossref', 'first-page': '220', 'DOI': '10.1016/j.resinv.2023.01.002', 'article-title': 'COVID-19 symptom-onset to diagnosis and diagnosis to treatment ' 'intervals are significant predictors of disease progression and ' 'hospitalization in high-risk patients: a real world analysis', 'volume': '61', 'author': 'Shimizu', 'year': '2023', 'journal-title': 'Respir Invest'}, { 'key': '10.1016/j.jinf.2023.08.016_bib58', 'article-title': 'Molnupiravir and risk of post-acute sequelae of Covid-19: cohort study', 'volume': '381', 'author': 'Xie', 'year': '2023', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.jinf.2023.08.016_bib59', 'unstructured': 'Pfizer, Inc. FDA Briefing Document. NDA# 217188. Drug name: nirmatrelvir ' 'tablets and ritonavir tablets copackaged for oral use. Pfizer, Inc.; ' 'March 16, 2023.'}, { 'key': '10.1016/j.jinf.2023.08.016_bib60', 'unstructured': 'Pfizer, Inc. PAXLOVID (nirmaltrevir [PF-07321332] tablets; ritonavir ' 'tablets). NDA 217188. Advisory committee briefing materials. Pfizer, ' 'Inc.; March 16, 2023.'}, { 'issue': '628', 'key': '10.1016/j.jinf.2023.08.016_bib61', 'doi-asserted-by': 'crossref', 'first-page': 'eabl7430', 'DOI': '10.1126/scitranslmed.abl7430', 'article-title': 'A phase 2a clinical trial of molnupiravir in patients with COVID-19 ' 'shows accelerated SARS-CoV-2 RNA clearance and elimination of ' 'infectious virus', 'volume': '14', 'author': 'Fischer', 'year': '2022', 'journal-title': 'Sci Transl Med'}, { 'issue': '3', 'key': '10.1016/j.jinf.2023.08.016_bib62', 'first-page': '147', 'article-title': 'SARS-CoV-2 viral load and shedding kinetics', 'volume': '21', 'author': 'Puhach', 'year': '2023', 'journal-title': 'Nat Rev Microbiol'}, { 'issue': '11', 'key': '10.1016/j.jinf.2023.08.016_bib63', 'doi-asserted-by': 'crossref', 'first-page': '1582', 'DOI': '10.1086/345722', 'article-title': 'Zanamivir prophylaxis: an effective strategy for the prevention of ' 'influenza types A and B within households', 'volume': '186', 'author': 'Monto', 'year': '2002', 'journal-title': 'J Infect Dis'}], 'container-title': 'Journal of Infection', 'original-title': [], 'language': 'en', 'link': [ { 'URL': '', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 10, 19]], 'date-time': '2023-10-19T23:06:49Z', 'timestamp': 1697756809000}, 'score': 1, 'resource': {'primary': {'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 11]]}, 'references-count': 63, 'journal-issue': {'issue': '5', 'published-print': {'date-parts': [[2023, 11]]}}, 'alternative-id': ['S0163445323005005'], 'URL': '', 'relation': {}, 'ISSN': ['0163-4453'], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'container-title-short': 'Journal of Infection', 'published': {'date-parts': [[2023, 11]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD ' 'randomized, placebo-controlled trial', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Journal of Infection', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': '', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2023 Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, ' 'USA and The Author(s). Published by Elsevier Ltd on behalf of The British ' 'Infection Association.', 'name': 'copyright', 'label': 'Copyright'}]}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop